Importantly, AOD9604 achieved these effects without activating the growth-promoting pathways that full-length growth hormone uses, which is why it doesnt cause the unwanted side effects of growth hormone therapy such as insulin resistance or abnormal growth
Davies, M., Chatterjee, S
Saxenda is typically prescribed for individuals with a body mass index (BMI) of: - 30 or higher (classified as obese), or - 27 or higher (overweight) with at least one weight-related condition, such as type 2 diabetes, hypertension, or high cholesterol
how soon after initiation of treatment did the patients go on to develop DME between control and those treated with GLP-1 agonists
She also emphasizes that she does not prescribe them for cosmetic weight loss